2026 International Congress Archives - Page 136 of 208

L-DOPA Metabolism as a Function Related to the Potency of iPSC-Derived Dopaminergic Progenitor cells

S. Hiramatsu, C. Naito, M. Fujiwara, T. Yamashita, K. Watanabe, T. Yamada, R. Yamaguchi (Kobe, Japan)
Lack of Association Between Polygenic Risk Scores for Parkinson’s Disease and Age at Onset, Freezing of Gait, or Psychosis

R. Shisgal, T. Davidy, A. Saar, S. Anis, T. Fay-Karmon, A. Sominski, M. Zhang, Z. Gan-Or, L. Grinbaum, S. Hassin-Baer (Ramat Gan, Israel)
Lactobacillus reuteri Y7 Improves Motor and Non-Motor Features Through Gut-Brain-Metabolic Modulation in a 6-OHDA Rat Model of Parkinson’s Disease

SP. Tsao, LY. Hsieh, YT. Chou, TH. Yeh, HY. Huang (Taipei City, Taiwan)
Large Language Models for Clinical Feature Suggestion from Parkinson’s Disease Clinical Notes

GY. Lee, HY. Kwon, S. Jo, M. Choi, N. Kim, SJ. Chung (Seoul, Republic of Korea)
Large-Scale Shotgun Mass Spectrometry in Parkinson’s Disease Plasma Identifies Novel Biomarker Candidates

S. Khosousi, L. Velayudhan, X. Yang, S. Lynham, P. Andrén, A. Hye, P. Svenningsson (London, United Kingdom)
Late Diagnosed Kufor Rakeb Syndrome Presenting as Drug Induced Parkinsonism

MG. Gultekin (Kayseri, Turkey)
Late onset chorea secondary to antiphospholipid syndrome with radiological correlation on brain FDG-PET: a case report.

A. Bonilla Tena, G. Lafuente Gómez, A. Contreras Chicote, B. Casa Fages, J. Pérez Sánchez, E. Luque Buzo, V. Pérez Olmo, F. Grandas Pérez (Madrid, Spain)
Late-Onset Ataxia, Tremor and Spastic Paraparesis associated with the a Novel CCDC88C Variant: Expanding the Phenotypic Spectrum of mutation in the CCDC88C gene

I. Sarac, H. Sarac, F. Borovecki (Zagreb, Croatia)
Late-Onset Bulbar-Predominant Neurodegeneration Associated With a Truncating AFG3L2 Variant: Expanding the Clinical Spectrum of AFG3L2-Related Disease

R. Sharma, A. Higinbotham, C. Chambers, G. Solorzano (Charlottesville, USA)
Late-Onset Huntington’s Disease Misdiagnosed as Post-Stroke Chorea: A Case Report

JSL. Lee, SY. You (Daegu, Republic of Korea)
Late-onset THAP-1 with SCA8 expansion mimicking functional movement disorder, case report.

ZH. Myrzayev, M. Mukhamadiyeva, D. Bagautdinov, CH. Shashkin (Almaty, Kazakhstan)
Latent Classes of Cognitive Decline in Parkinson’s Disease: Neuroimaging and Neurodegenerative Blood Biomarker Correlates

MC. Mckenna, M. Pasternak, R. Alesker, S. Mirza, S. Black, C. Marras, M. Binns, D. Breen, K. Fishman, D. Grimes, B. Levine, P. Mclaughlin, A. Troyer, R. Bartha, H. Zetterberg, A. Lang, M. Masellis (Toronto, Canada)
Latent Clinical States and Longitudinal Transitions in Prodromal Lewy Body Disease: A Data-Driven Analysis from the NaT-PROBE Study

K. Fuse, K. Hiraga, Y. Yada, K. Nakao, Y. Saito, T. Fukushima, D. Tamakoshi, T. Uematsu, T. Tsuboi, M. Suzuki, M. Sato, M. Yamamoto, H. Shimizu, M. Wakai, N. Honda, M. Katsuno (Nagoya, Japan)
Latin American (LatAM) Progressive Supranuclear Palsy Consortium

J. Parmera, M. Oliveira, V. Maciel, G. Martins, A. Coutinho, A. Schuh, S. Camargos, B. Couto (São Paulo, Brazil)
Lead Asymmetry and Axial Symptom Response to Deep Brain Stimulation in Parkinson’s Disease: A Synthetic Pilot Modeling Study

E. Yildirim, M. Kok, H. Kayacan, B. Samanci, G. Kenangil, A. Zirh, Y. Samanci (Istanbul, Turkey)
Levels of cytokines in the cerebrospinal fluid of patients depending on the stages of Parkinson’s disease

B. Amonov, B. Muminov, E. Abduqodirov, R. Matmurodov, S. Jumanazarova (Tashkent, Uzbekistan)
Levels of IgA and IgG concentrations by stage of Parkinson’s disease

S. Jumaniyozov, R. Matmurodov, H. Daminova, S. Inoyatova (Tashkent, Uzbekistan)
Levodopa dosing regimen influences repetitive tongue force maintenance in Parkinson’s disease

S. Hayasaka, K. Hatori, K. Sato, T. Ogawa, T. Hatano, T. Fujiwara (Urayasu, Japan)
Levodopa Initiation in Phase 3 Trials of Tavapadon, a Selective D1/D5 Agonist for Early Parkinson’s Disease

W. Ondo, G. Stebbins, J. Eubanks, M. Rollins Hatcher, T. Nicholson, J. Ma (Houston, USA)
Levodopa Responsiveness and Motor Complication Trajectories in Parkinson’s Disease by α-Synuclein Seed Amplification Assay Status

H. Azizi, SM. Fereshtehnejad, R. Moqadam, M. Dadar, A. Siderowf, A. Dagher, Y. Zeighami (Montreal, Canada)
Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson’s Disease: Extension Study of Long-term outcomes of Single Centre experience

H. Alhodaif, Y. Alkhodair, S. Alqahtani, B. Bohlega, A. Aldakheel (Riyhadh, Saudi Arabia)
Levodopa-Induced Dyskinesia Predicts Falls, Fall-Related Injuries, and Their Consequences in Parkinson’s Disease: A Prospective PPMI Cohort Study

P. Pelicioni, L. Santos, S. Freitas, P. Nobrega-Sousa, K. Delbaere (Sao Paulo, Brazil)
Levodopa-Induced Dyskinesias in Patients with Parkinson’s Disease in the Uzbek Population

G. Isroilova, Z. Sayfitdinkhuzhaev (Tashkent, Uzbekistan)
Levodopa-induced peak-dyskinesia and motor fluctuations in corticobasal syndrome

N. Caballol, A. Cámara, L. Planellas, C. Painous, A. Peral, A. Planas-Ballvé, P. Lombardo, A. ávila, Y. Compta (Sant Joan Despí, Spain)
Levodopa-Responsive Dystonia in Adenylosuccinate Lyase (ADSL) Deficiency Treated With Bilateral GPi Deep Brain Stimulation

K. Ibarra, M. San Luciano (San Francisco, USA)
Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Provides Sustained Improvement In Quality Of Life In Advanced Parkinson’s For Up To Two Years

S. Singh, N. Smith, B. Amlani (Reading, United Kingdom)
Levodopa–Entacapone–Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: a Four-Year Real-Life Experience

J. Szasz, V. Constantin, K. Orban Kis, R. Szasz, S. Bataga, R. Neagoe, M. Ciorba, K. Kelemen, I. Mihaly, K. Biro, S. Szatmari (TARGU MURES, Romania)
LFP-Based Deep Brain Stimulation Programming and Transition to Adaptive Deep Brain Stimulation in a Patient with Parkinson’s Disease: A Case Report from Thailand

O. Phokaewvarangkul, N. Likhitwitayawuid, K. Sanyawut, N. Rattanapitak, R. Bhidayasiri (Bangkok, Thailand)
Life Changing Diagnoses; Distinguishing Holmes Tremor from Functional Tremor

A. Hunt, J. Martindale, M. Siddiqui (Winston-Salem, USA)
Lifestyle Changes After Parkinson’s Disease Diagnosis: Associations with Age, Sex, Disease Duration, and Self-Perceived Quality of Life

J. Bestoso, R. Sanjinez, R. Huaiquil (Buenos Aires, Argentina)
Lifestyle Factors as Predictors of Progression in Parkinson’s Disease

X. Zhang, X. Chen, C. Christine, A. Hung, M. Schwarzschild, A. Ascherio, M. Flores Torres, K. Bjornevik (Boston, USA)
Limited Evidence for TPBG Variants in Parkinson’s Disease Risk Across Global Ancestries

R. Laban, R-A. Steopoaie, C. Herghelegiu, N. Ioana, I. Salazar, A. López Lobato, B. Popescu, A. Noyce, M. Periñan, P. Reyes, A. Zirra (London, United Kingdom)
Linear-Time RWKV Multimodal Fusion of Smartphone Audio and Wearable Signals for Mild Cognitive Impairment Screening

D. Hemmerling, JH. Yun, J. Krzywdziak, B. Eljasiak, A. Pruszek, L. Lazarski, M. Grzeszczyk, T. Brzózka, W. Szecówka, W. średniawa, H. Lee, W. Baek, S. Yoon, M. Matuszewski (Seoul, Republic of Korea)
Lingual tremor secondary to ischemic stroke of the left middle cerebral artery. Another movement disorder with cortical localization?

A. Bonilla Tena, S. Secades, A. Contreras Chicote, B. Casa Fages, E. Luque Buzo, J. Pérez Sánchez, V. Pérez Olmo, A. Iglesias Mohedano, S. Gomez, F. Grandas Pérez (Madrid, Spain)
Linking Motor and Non-Motor Fluctuations in Parkinson’s Disease

A. Shaaban, A. Gaber, H. Salem, SH. Khater, A. Mansour (Cairo, Egypt)
Lipid Alterations in Central Nervous System and Plasma During Early Stages of Parkinson’s Disease

P. Thakur, U. Agarwal (Thiruvananthapuram, India)
Lived Experience of Parkinson’s Disease in Six African Countries: A Qualitative, Multi-site Transforming Parkinson’s Care in Africa (TraPCAf) Study

N. Fothergill-Misbah, G. Abdulai, M. Agoriwo, W. Animdife, S. Asibey, S. Asmare, M. Breckons, E. Bruce, B. Calys-Tagoe, N. Coleman, A. Helmy, E. Jembere, J. Lumsdon, B. Mghendi, B. Mushengezi, R. Mwezi, O. Orogun, S. Urasa, R. Walker, N. Okubadejo (Newcastle Upon Tyne, United Kingdom)
Lived Experiences and the Weight of Parkinson’s Caregiving in Kenya

B. Mghendi, D. Sokhi, N. Fothergill-Misbah (Nairobi, Kenya)
Local Brain Structural Changes After Transcranial Magnetic Stimulation for Essential Tremor: An Exploratory MRI Analysis

J. Xu, X. Bai, X. Liu, H. Cao (Xi'an, Shaanxi Province, China)
Local Field Potential–Guided versus Clinically- Guided Electrode Identification For Continuous GPi -DBS in Parkinson’s Disease

A. Kishore, M. Girija, S. Joshua, A. Nair, A. Hynse (Kochi, India)
Local Field Potentials (LFP) Insights in the Treatment of X-linked Dystonia-Parkinsonism with Deep Brain Stimulation of the Subthalamic Nucleus

J. Chen, W. Tse (New York, USA)
Local Glymphatic Dysfunction in Multiple System Atrophy: Insights from Multimodal MRI

J. Pardo, C. Martín-Barceló, C. Roura, C. García-Vicente, C. Falcon, A. Campabadal, R. Sala-Llonch, N. Bargalló, C. Painous, A. Pérez, A. Cámara, M. Buongiorno, Y. Compta, C. Junqué, B. Segura, MJ. Martí (Barcelona, Spain)
Locus Coeruleus-Thalamic Circuit Degeneration in Parkinson’s Disease

XL. Cui, MF. Cai, YH. Zhang (Guangzhou, Guangdong Province, China)
Logopenic Aphasia After Thalamotomy in Parkinson’s Disease: A Case Report

İ. Sipahi, R. Yılmaz, ş. Akça Kalem, B. Samanci, E. şahin, H. Hanağası, B. Bilgiç (İstanbul, Turkey)
Long-term 5-year follow-up of unilateral FUS thalamotomy for essential tremor

E. Natera-Villalba, E. Salinas, A. Huerta, A. Jiménez-Huete, GM. Díaz-Taveras, MA. Gorospe, A. Martín-Bastida, PM. Cortadi La-Villa, I. Avilés-Olmos, CA. Sánchez Catasús, A. Arcadi, LH. González-Quarante, J. Guridi, MC. Rodríguez Oroz (Pamplona, Spain)
Long-Term Effects of Repeated Home-Based tDCS on Language Production in Parkinson’s Disease

N. Němcová Elfmarková, ľ. Nováková, K. Novotný, D. Kováč, J. Mekyska, I. Rektorová (Brno, Czech Republic)
Long-Term Efficacy and Determinants of Motor and Quality-of-Life Outcomes Following Bilateral GPi-DBS in Dystonia

G. Yılmaz çakan, B. Arı, N. Helvacı Yılmaz, Y. Samancı, G. Kenangil, A. Zırh (Istanbul, Turkey)
Long-term evolution of deep brain stimulation parameters in Parkinson´s Disease: A 6-year analysis.

D. Oropeza-Velázquez, A. Morales-Velez, LA. Haro-Santillan, M. Velázquez-Vaquero, D. Oropeza-Canto, E. Peña-Andrade, Y. Tiburcio-Núñez, D. Blumenkron-Marroquín, A. Romero-Pérez, CE. Chávez-Donis (Puebla, Mexico)
Long-term exposure to fine particulate matter (PM2.5) is associated with earlier onset of Parkinson’s disease: a retrospective population-based cohort study

C. Santoro, M. Pesare, F. Catino, F. Castellana, N. Pilolli, A. Macerollo, G. Boero, R. Sardone (Taranto, Italy)
Long-Term Instability of GPi Gamma Oscillations in Parkinson’s Disease: A Case Study

Q. Yuan, J. Dang, T. Mehta, J. Cagle, C. de Hemptinne, J. Wong (Gainesville, USA)
Long-Term Open-Label Data on the GCase Modulator GT-02287 in People with Parkinson’s Disease

R. Pozzi, T. Ignoni, M. Bosetti, A. Barassi, M. Desciscio, A. Lehn, R. Schwartz, D. Thyagarajan, J. Taylor, J. Hannestad (Lugano, Switzerland)
Long-term outcomes and real-world implementation of adaptive deep brain stimulation in Parkinson’s disease

V. Witzig, J. Busch, J. Kaplan, J. Behnke, L. Drescher, J. Habets, A. Kühn (Berlin, Germany)
Long-term safety of deep brain stimulation (DBS): Real-world evidence

J. Joseph, Y. Pathak, C. Salazar, A. Benison (Austin, USA)
Long-term Safety of Opicapone in Parkinson’s Disease Patients with First Signs of Wearing-off

JJ. Ferreira, F. Stocchi, A. Antonini, O. Rascol, G. Ebersbach, J. Kulisevsky, N. Pavese, G. Hoglinger, D. Ramos, J-F. Rocha, HC. Brigas, J. Holenz, W. Poewe (Lisboa, Portugal)
Long-term therapeutic effects of repetitive transcranial magnetic stimulation combined with lidocaine injection (rTMS-LI) in dystonia

N. Muraser, R. Urushihara, H. Shimazu, S. Matsumoto, K. Satoh, K. Asanuma, R. Kaji (Nara city, Japan)
Long-term utilization of onabotulinumtoxinA for the treatment of cervical dystonia

R. Barbano, K. Dashtipour, D. Safarpour, M. Sadeghi, J. Zhao, K. Ifantides, A. Ukah, B. Jabbari (Rochester, USA)
Long‑term dose-effect patterns with incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in cervical dystonia: multicenter real‑world analysis

B. Waeschle, P. Albrecht, J. Lee, T. Kölsche, R. Jansen, P. Sobolewski, S. Sánchez Valiente, E. López Valdés, P. Mir, S. Jesús, E. Ojeda Lepe, E. Papuć, P. Sánchez Alonso, G. Salazar, G. Comes, H. Stark (Frankfurt, Germany)
Longitudinal Association Between Baseline CSF GFAP Levels and Clinical Progression in Parkinson’s Disease A PPMI Study

Z. Huseynli (Istanbul, Turkey)
Longitudinal Changes and Clinical utility of the Neurological Pupillary Index in De Novo Parkinson’s Disease

JSL. Lee, SY. You (Daegu, Republic of Korea)
Longitudinal cognitive trajectories and predictors of dementia conversion in Parkinson’s disease

N. Sánchez-Lorenzo, K. Sánchez-Ramírez, M. Rocha-de-León, A. Beltrán-Torres, E. Ramírez-Benitez, A. Cervantes-Arriaga, M. Rodríguez-Violante (Pachuca, Mexico)
Longitudinal cognitive variability in isolated and probable REM sleep behaviour disorder using the Trail Making Test

H. Chohan, S. Water, L. Pérez-Carbonell, G. Leschziner, T. Periñán, B. Huxford, S. Eriksson, J. Bestwick, A. Schrag, A. Noyce, C. Simonet (London, United Kingdom)
Longitudinal Decline of Alanine Aminotransferase Activity in Parkinson’s Disease and Its Association with Disease Duration

G. Maayan Eshed, M. Shemesh, N. Omer, R. Alcalay, M. Gana-Weisz, O. Goldstein, A. Mirelman, A. Thaler (Tel Aviv, Israel)
Longitudinal Evolution of Freezing of Gait after STN-DBS in Parkinson’s disease: Insights from the GAIT-DBS multicenter Study

L. Díaz-Feliz, F. Escamilla-Sevilla, O. Mateo-Sierra, A. Sánchez-Gómez, I. Aracil-Bolaños, E. Muñoz, JM. Arbelo, A. Rodriguez-Sanz, L. Triguero-Cueva, A. Campolongo, E. González-Turiño, B. Pascual-Sedano, B. Delacasa Fages (Las Palmas de Gran Canaria, Spain)
Longitudinal evolution of impulsive-compulsive behaviors and their prognostic value in Parkinson’s disease

M. Rocha-de-León, A. Beltrán-Torres, N. Sánchez-Lorenzo, K. Sánchez-Ramírez, D. Nafate-Wences, A. Cervantes-Arriaga, M. Rodríguez-Violante (Mexico City, Mexico)
Longitudinal gait change after unilateral MRgFUS thalamotomy or subthalamotomy in Parkinson’s disease

E. Salinas Jaime, G. Diaz-Taveras, P. Lecumberri Villamediana, E. Natera-Villalba, A. Martin-Bastida, L. Gonzalez-Quarante, A. Arcadi Da-Silva, P. Cortadi La-Villa, C. Sanchez-Catasus, M. Rodriguez-Oroz (Pamplona, Spain)
Longitudinal gait changes after unilateral and bilateral MRgFUS thalamotomy in Essential Tremor

E. Salinas Jaime, G. Diaz-Taveras, P. Lecumberri Villamediana, E. Natera-Villalba, A. Martin-Bastida, A. Arcadi Da-Silva, L. Gonzalez-Quarante, PM. Cortadi La-Villa, C. Sanchez-Catasus, M. Rodriguez-Oroz (Pamplona, Spain)
Longitudinal motor network responses to pallidal DBS in cervical dystonia: an ongoing DBS-fMRI study

E. Cito, S. Deutsch, S. Wang, D. Mikhael, J. Ostrem, M. San Luciano, I. Bledsoe, M. Morrison (San Francisco, USA)
Longitudinal shifts in goal-directed and habitual control relate to tic severity and cortico-striatal connectivity in adolescents with Tourette syndrome

C. Lecomte, TM. Sartoris, C. Atkinson-Clement, B. Beranger, C. Tarrano, FX. Lejeune, R. Valabrègue, A. Hartmann, V. Czernecki, E. Roze, C. Rosso, P. Pouget, C. Gallea, Y. Worbe (Paris, France)
Longitudinal Weight/BMI Trajectories and Their Clinical Impact on Parkinson’s Disease.

K. Sánchez-Ramírez, N. Sánchez-Lorenzo, A. Beltrán-Torres, M. Rocha-de-León, E. Ramírez-Benitez, A. Cervantes-Arriaga, M. Rodríguez-Violante (Mexico City, Mexico)
Longitudinal α-synuclein Seed Amplification Assay Analysis of PPMI Participants

L. Concha-Marambio, C. Gochanour, J. Yin, C. Farris, Y. Ma, D. Lafontant, T. Simuni, K. Marek, T. Tropea, D. Coughlin (Iowa, USA)
Loss of NAA60-mediated N-terminal acetylation cause primary brain calcification with disturbed Golgi- and phosphate-maintenance functions

A. Siggervåg, å. Bekkelund, C. Leerink, L. Alabdi, A. Khan, H. Aldhalaan, R. Helaby, O. Abuyousef, A. Melbye, N. Glomnes, J. Saraste, F. Alkuraya, H. Aksnes (Bergen, Norway)
Low-dose ketamine reduces dopamine 2 receptor-like agonist-induced dyskinesia in a preclinical model

T. Falk, R. Parmar, J. Meredith, J. Castro, E. Smith, M. Bartlett, S. Sherman (Tucson, USA)
Low-Intensity Treadmill Training Preserves Motor Function and Muscle Mass Through Mitochondrial and Antioxidant Regulation in a Rat Model of Parkinson’s Disease

TH. Yeh, CC. Chiu, HY. Huang (Taipei City, Taiwan)
LRRK2 G2019S Drives Lysosomal Lipid Remodeling and Inflammation in Human iPSC-Derived Microglia

M. Tziortziou, M. Jakubec, I. Goglia, K. Badanjak, P. Seibler, J. Penny, G. Dittmar, S. Pereira, P. Antony, E. Glaab, A. Grünewald (Esch-sur Alzette, Luxembourg)
LRRK2 in Focus: A Global Browser Linking Genetic Diversity to Functional Effects

S. Grant, V. van Midden, E. Fernandez, M. Cham, E. Sammler, D. Alessi, H. Morris, C. Blauwendraat, A. Singleton, L. Lange (Bethesda MD, USA)
LRRK2 Mutation Spectrum and Association Study in a Multi-ethnic Cohort of Malaysian Parkinson’s Disease Patients

K. Lim, J. Lim, M. Periñan, Y. Tay, T. Toh, L. Lit, A. Khairul Anuar, H. Ding, K. Ibrahim, A. Mawardi, Y. Chia, J. Ooi, T. Lim, J. Schee, Y. Beh, L. Screven, S. Bandres-Ciga, S. Lim, A. Tan, A. Ahmad-Annuar (London, United Kingdom)
Lu AF28996, a Novel Oral D1-like/D2-like Receptor Agonist, May Improve Motor Complications in People with Parkinson’s Disease: Results from an 18-week open-label, Phase 1b Trial

AM. Højer, A. Cucca, C. Linander, L. Creuwels, M. Pedersen, D. Meulien (Copenhagen, Denmark)
Lysosomal polygenic risk score in Parkinson disease across populations.

W. Sun, K. Brockmann, C. Schulte, T. Gasser, M. Tan (Tübingen, Germany)